Latest Mental Health News

Emyria has secured a multi-year funding extension with Medibank to launch its Empax mental health programs in Brisbane, marking a key step in its national expansion. This insurer-backed initiative aims to improve access to treatment for complex conditions like treatment-resistant depression and PTSD.

Tryptamine Therapeutics has enrolled the first patient in its pioneering clinical trial testing TRP-8803, an IV-infused psilocin formulation, for Binge Eating Disorder. The study aims to evaluate safety and efficacy, potentially reshaping treatment options for millions.

RAM Essential Services Property Fund (REP) reports a Q1 FY26 distribution in line with guidance and reaffirms its full-year yield target while progressing its strategic transition to a healthcare-focused REIT.

Emyria secures a multi-year funding agreement with Medibank to support its Treatment-Resistant Depression program, marking a first for insurer-backed psychotherapy in Australia.

Ramsay Health Care has clarified that its underlying earnings for FY25 aligned closely with market consensus, despite a significant non-cash impairment impacting statutory profits. The company confirms compliance with ASX disclosure rules amid share price volatility.

Dexus has announced its 18.0 cents per security distribution for the first half of 2025, alongside robust full-year results that highlight a resilient portfolio and disciplined capital management. The company signals confidence with a steady outlook despite ongoing economic uncertainty.

Hearts and Minds Investments Limited (HM1) reported a stellar FY25 with total comprehensive income soaring to $124.8 million, nearly doubling the prior year, alongside a dividend increase and sustained philanthropic commitments.

Future Generation Global Limited reported a notable decline in half-year profits but raised its fully franked interim dividend, underscoring confidence in its investment strategy and ongoing commitment to youth mental health initiatives.

InhaleRx has secured ethics approval to begin a Phase 1 clinical trial of IRX-616a, a synthetic cannabidiol inhaler aimed at providing fast relief for panic disorder. The fully funded study will assess safety and pharmacokinetics in healthy volunteers.

Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.

Ramsay Health Care reported a 6.8% revenue increase and a modest rise in underlying profit for FY25, despite a significant impairment in its UK mental health division. The company maintains a strong dividend and outlines a cautiously optimistic outlook for FY26.

Medibank Private Limited reported a robust FY25 with an 8.5% rise in underlying net profit after tax and an 8.4% increase in fully franked dividends, driven by growth in both resident and non-resident health insurance segments and expanding health services.